Document is current
Any future updates will be listed below
-
Authors
Lee, Kwangwoon https://orcid.org/0000-0002-2021-5186
Barone, Marco https://orcid.org/0000-0001-7184-2940
Waterbury, Amanda L. https://orcid.org/0000-0002-4473-2866
Jiang, Hanjie https://orcid.org/0000-0001-6090-4552
Nam, Eunju https://orcid.org/0000-0003-0801-9331
DuBois-Coyne, Sarah E.
Whedon, Samuel D. https://orcid.org/0000-0002-3745-5645
Wang, Zhipeng A. https://orcid.org/0000-0002-5693-7359
Caroli, Jonatan
Neal, Katherine https://orcid.org/0000-0003-4171-1944
Ibeabuchi, Brian
Dhoondia, Zuzer https://orcid.org/0000-0002-0390-8140
Kuroda, Mitzi I. https://orcid.org/0000-0003-0840-3608
Liau, Brian B. https://orcid.org/0000-0002-2985-462X
Beck, Samuel https://orcid.org/0000-0002-0184-8367
Mattevi, Andrea https://orcid.org/0000-0002-9523-7128
Cole, Philip A. https://orcid.org/0000-0001-6873-7824
- License Information
-
More Information
Article History
Received: 13 September 2023
Accepted: 7 June 2024
First Online: 4 July 2024
Competing interests
: P.A.C. is a co-founder of Acylin Therapeutics, which is involved in developing epigenetic agents, and has been a consultant for the pharmaceutical companies AbbVie and Constellation. He also is a co-inventor on US patent 11,565,994 B2 that concerns LSD1 and CoREST complex inhibitors. B.B.L. has received research funding from Eisai and AstraZeneca and is a shareholder and member of the scientific advisory board of Light Horse Therapeutics. The other authors declare no competing interests.
